Related Experiment Video
Updated: Sep 3, 2025
04:44
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
437
Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors
Calogero Crapanzano1, Ilaria Casolaro2, Chiara Amendola3
1Azienda Sanitaria Provinciale di Agrigento, Centro Salute Mentale Licata, Licata,Italy.
Summary
Lithium and valproate are key bipolar disorder treatments. Patient factors and illness phase guide optimal selection for mania, depression, or prevention, improving treatment strategy.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Neuroscience
Background:
- Lithium and valproate are established treatments for bipolar disorder.
- Treatment response varies based on illness phase and individual patient characteristics.
Purpose of the Study:
- To review clinical and preclinical factors influencing lithium versus valproate selection in bipolar disorder.
- To summarize current guidelines and clinical trial data on these mood stabilizers.
Main Methods:
- Narrative review of clinical trials.
- Analysis of international treatment guidelines for bipolar disorder.
Main Results:
- Lithium is effective for acute mania and prophylaxis; preferred in specific patient profiles (e.g., family history, low comorbidity).
- Valproate is more effective for acute mania than prophylaxis; may suit patients with higher episode burden or comorbidities.
- Neither is recommended for acute mixed states or bipolar depression.
Conclusions:
- Individual pretreatment variables and illness phase are crucial for selecting lithium or valproate.
- Tailoring treatment based on these factors can optimize bipolar disorder management.
- Further research may refine personalized pharmacotherapy strategies.
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
315
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
315
01:30Bipolar Disorder
139
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
139
01:26Psychosis: Goals of Pharmacotherapy
202
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
202
01:30Electroconvulsive Therapy
138
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
138
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
426
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
426
01:28Drug Therapy
92
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
92